改进的神经网络与多任务学习用于阿尔茨海默氏症疾病分类
Xin Zhang1, Le Gao1, Zhimin Wang1
1School of Electronic and Information Engineering, Wuyi University, Jiangmen, 529000, China.
Heliyon
|March 4, 2024
概括
一个新的AI模型,ADnet,通过MRI扫描改善了阿尔茨海默病 (AD) 的检测. 这种增强的神经网络显示出显著的准确性增长,有助于早期诊断和干预阿尔茨海默病和轻度认知障碍 (MCI).
科学领域:
- 人工智能的人工智能
- 医疗成像医学成像
- 神经学 神经学
背景情况:
- 阿尔茨海默病 (AD) 是一个重大的健康挑战,治疗选择有限.
- 早期发现AD对于及时干预和管理至关重要.
- 目前的诊断方法可能具有侵入性或缺乏足够的灵敏度.
研究的目的:
- 开发和评估一个增强的神经网络,ADnet,以使用MRI扫描改进阿尔茨海默病的检测.
- 研究将深度可分离卷积,ELU激活和SE模块纳入基于VGG16的AD分类模型的有效性.
- 评估辅助回归任务对初级分类性能的影响.
主要方法:
- 使用基于VGG16的神经网络架构,称为ADnet.
- 实施深度可分离的卷积,以减少模型参数.
- 用ELU激活和集成的Squeeze-and-Excitation (SE) 模块取代ReLU,以增强功能提取.
- 雇佣多任务学习,包括临床痴呆症和精神状态得分回归以及MRI分类.
主要成果:
- 在阿尔茨海默病 (AD) 与认知正常 (CN) 分类方面,ADnet显示了比基线VGG16的4.18%的准确性改善.
- 在轻度认知障碍 (MCI) 与CN分类之间实现了6%的准确性改进.
- 集成的SE模块提高了特征提取效率,提高了诊断准确度.
结论:
- 通过MRI数据,ADnet为人工智能驱动的阿尔茨海默病早期检测提供了有希望的进步.
- 架构增强和多任务学习策略显著提高了分类准确性.
- 这种方法为医疗专业人员在早期诊断和干预AD和MCI方面提供了宝贵的支持.
相关概念视频
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481


